Canagliflozin Cuts Hospitalization Risk for HF in Type 2 Diabetes Patients
The results showed canagliflozin was associated with a significant reduction in risk of CV death or HHF by 22%.
ACC.18
Use of Carvedilol for Anthracycline Cardiotoxicity Prevention Investigated
Carvedilol does not prevent reduction in LVEF in breast cancer but is linked to lower troponin I levels
Febuxostat Linked to Increased Death Risk in Gout Patients With Heart Disease
Participants were followed for a median of 32 months.
Ticagrelor vs Clopidogrel: TIMI Major Bleed Rates Compared Post-Fibrinolysis
After 30 days of treatment the analysis found that major bleeding – the most common complication with blood thinners – occurred at the same level (0.7%) for patients in both treatment groups
Want to read more?
Please login or register first to view this content.
